Evidence map›Paper›PMID 21149651›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2011

Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis.

Janine Giese-Davis, Kate Collie, Kate M S Rancourt, Eric Neri, Helena C Kraemer, David Spiegel

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 238 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
238citing papers in PubMed, 15 pooled it
12.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

238 citing papers in PubMed, 15 syntheses or guidelines pooled it, 464 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Interventions for multidimensional aspects of breast cancer-related fatigue: a meta-analytic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Guideline
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Distress is Interdependent in Patients and Caregivers with Newly Diagnosed Incurable Cancers.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2017
    Trial
  20. Trial

178 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Janine Giese-DavisStanford University School of Medicine, Stanford, CA, USA. jgieseda@ucalgary.ca
Kate Collie
Kate M S Rancourt
Eric Neri
Helena C Kraemer
David Spiegel
Alberta Cancer Foundation · CA

Funding

Stress, The HPA and Health in AgingP01AG018784 · NIA · STANFORD UNIVERSITY · PI SPIEGEL, DAVID · 2001 to 2008
$8.7M
Sleep, Circadian, Hormonal Dysregulation, and Breast Cancer SurvivalR01CA118567 · NCI · STANFORD UNIVERSITY · PI SPIEGEL, DAVID · 2006 to 2010
$2.3M
PSYCHOSOCIAL TREATMENT EFFECTS ON CANCER SURVIVALR01MH047226 · NIMH · STANFORD UNIVERSITY · PI SPIEGEL, DAVID · 1990 to 2004
$2.0M
NCI NIH HHS R01 CA118567NCI NIH HHS R01CA118567NIA NIH HHS P01 AG018784NIA NIH HHS P01AG018784NIMH NIH HHS 5R01MH047226NIMH NIH HHS R01 MH047226
6 · The paper itself

Abstract

purposeNumerous studies have examined the comorbidity of depression with cancer, and some have indicated that depression may be associated with cancer progression or survival. However, few studies have assessed whether changes in depression symptoms are associated with survival.

methodsIn a secondary analysis of a randomized trial of supportive-expressive group therapy, 125 women with metastatic breast cancer (MBC) completed a depression symptom measure (Center for Epidemiologic Studies-Depression Scale [CES-D]) at baseline and were randomly assigned to a treatment group or to a control group that received educational materials. At baseline and three follow-up points, 101 of 125 women completed a depression symptom measure. We used these data in a Cox proportional hazards analysis to examine whether decreasing depression symptoms over the first year of the study (the length of the intervention) would be associated with longer survival.

resultsMedian survival time was 53.6 months for women with decreasing CES-D scores over 1 year and 25.1 months for women with increasing CES-D scores. There was a significant effect of change in CES-D over the first year on survival out to 14 years (P = .007) but no significant interaction between treatment condition and CES-D change on survival. Neither demographic nor medical variables explained this association.

conclusionDecreasing depression symptoms over the first year were associated with longer subsequent survival for women with MBC in this sample. Further research is necessary to confirm this hypothesis in other samples, and causation cannot be assumed based on this analysis.

Indexed as

Self-Help GroupsAdultBreast NeoplasmsDepressionDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateMiddle AgedProportional Hazards ModelsPsychiatric Status Rating ScalesQuality of LifeRisk AssessmentRisk FactorsSurvivorsTime Factors

Identifiers

PMID21149651
PMCPMC3058287
OpenAlexW2168746889

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.